Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Total Debt (2018 - 2019)

10x Genomics (TXG) has disclosed Total Debt for 2 consecutive years, with $29.7 million as the latest value for Q4 2019.

  • Quarterly Total Debt changed 0.14% to $29.7 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $29.7 million through Dec 2019, changed 0.14% year-over-year, with the annual reading at $29.7 million for FY2019, 0.14% changed from the prior year.
  • Total Debt hit $29.7 million in Q4 2019 for 10x Genomics, roughly flat from $29.7 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $29.7 million in Q4 2019 to a low of $29.7 million in Q4 2018.